CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
Doreen Su Yin TanJernice Wan Xin AwMichael WintherLiuh Ling GohHean Yee OngEric WeeJianjun LiuHan Kiat HoPublished in: Journal of clinical pharmacy and therapeutics (2019)
In our multivariate analysis, LoF-Clopidogrel, malay ethnicity, diabetics and use of proton pump inhibitors were independent predictors of MACE. There were numerically more bleeds in LoF subjects who were on prasugrel compared with Clopidogrel (23.5% vs 11%, P = .082). Our data corroborate with current findings on platelet reactivity testing, suggesting that the assay would not be sensitive enough to pick up sufficient 'at-risk' subjects as compared to the use of CYP2C19 genotyping.
Keyphrases
- acute coronary syndrome
- cardiovascular events
- percutaneous coronary intervention
- antiplatelet therapy
- coronary artery disease
- end stage renal disease
- high throughput
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- gene expression
- genome wide
- big data
- type diabetes
- data analysis
- metabolic syndrome
- patient reported outcomes
- adipose tissue
- patient reported
- single cell
- adverse drug
- glycemic control
- weight loss